Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Opdivo
Biotech
ESMO data show extent of Bristol Myers-Nektar bempeg catastrophe
The response rate among participants who received Opdivo as a single agent was higher, suggesting that if anything bempeg made things worse.
Nick Paul Taylor
Sep 9, 2022 5:36am
PACT Pharma culls lead asset, diverts 54 staffers to new venture
Aug 24, 2022 5:30pm
BMS, Nektar end $3.6B I-O program after 2 more late-stage flops
Apr 15, 2022 6:55am
BMS-Nektar's Opdivo combo therapy fails phase 3 in melanoma
Mar 14, 2022 9:40am
CytoDyn's shareholders have a plan to get leronlimab approved
Sep 24, 2021 11:37am
BMS melanoma, genitourinary commercial lead heads to miR
Aug 13, 2021 9:45am
